Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis.
Haesuk ParkRaj DesaiXinyue LiuSteven M SmithJuan Hincapie-CastilloLinda HenryAmie GoodinSaraswathi GopalCarl J PepineRajesh MohandasPublished in: Clinical journal of the American Society of Nephrology : CJASN (2022)
The Medicare reimbursement policy and Food and Drug Administration-recommended erythropoietin-stimulating agent dosing changes were associated with lower erythropoietin-stimulating agent use and lower hemoglobin levels. These changes in anemia care were associated with lower risks of major adverse cardiovascular event, stroke, mortality, and heart failure but higher risk of acute myocardial infarction among adults receiving hemodialysis.
Keyphrases
- cardiovascular events
- healthcare
- affordable care act
- chronic kidney disease
- coronary artery disease
- acute myocardial infarction
- heart failure
- end stage renal disease
- cardiovascular disease
- drug administration
- public health
- palliative care
- atrial fibrillation
- health insurance
- peritoneal dialysis
- quality improvement
- mental health
- left ventricular
- human health
- percutaneous coronary intervention
- recombinant human
- pain management
- type diabetes
- emergency department
- risk factors
- risk assessment
- chronic pain
- cardiac resynchronization therapy
- brain injury